12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Linaclotide regulatory update

Ironwood said FDA told the company that it will not schedule an advisory committee meeting to discuss an NDA for linaclotide, which is under review for chronic constipation and irritable bowel syndrome with constipation...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >